Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to present its innovative technology at the upcoming Venture Summit Virtual Connect conference, hosted by youngStartup Ventures from July 6-8, 2021.
Sonic Incytes is among the top innovators from the technology, cleantech, life sciences, healthcare and fintech sectors chosen to present to an exclusive audience of venture capitalists, private investors, investment bankers, corporate investors and strategic partners.
Sonic Incytes CEO George Aliphtiras will present VelacurTM, the first handheld 3D liver health assessment solution to tackle the emerging fatty liver disease (NASH) crisis, on July 7.
For more information, visit: https://youngstartup.com/vcglobal21/
